Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation

Pharmacogenetics and Genomics

Volumn 23, Issue 10, 2013, Pages 509-517

  Rojas, Luis E ^a,b   Herrero, María J ^b   Bosó, Virginia ^b   García Eliz, María ^c   Poveda, José L ^b   Librero, Julian ^e   Aliño, Salvador F ^b,c,d  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d UNIVERSITY OF VALENCIA   (Spain)

^e Health Services Research Network in Chronic Diseases (RESISSEC)   (Spain)

Author keywords

CYP3A5 polymorphism; liver transplantation; meta analysis; tacrolimus

Indexed keywords

CYTOCHROME P450 3A5; TACROLIMUS;

DRUG BLOOD LEVEL; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFORMATION RETRIEVAL; LIVER TRANSPLANTATION; ORGAN DONOR; PRIORITY JOURNAL; REVIEW;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CYTOCHROME P-450 CYP3A; GENETIC VARIATION; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; LIVING DONORS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS; TRANSPLANTATION; YOUNG ADULT;

EID: 84885059588     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283642fb3     Document Type: Review

References (39)

1. Grevel J. Area-under-the-curve versus trough level monitoring of cyclosporine concentration: Critical assessment of dosage adjustment practices and measurement of clinical outcome. Ther Drug Monit 1993; 15:488-491.
2. Jusko WJ. Analysis of tacrolimus (FK 506) in relation to therapeutic drug monitoring. Ther Drug Monit 1995; 17:596-601.
3. Armstrong VW, Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem 2001; 34:9-16.
4. Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD, et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 2006; 34:836-847.
5. Choi JH, Lee YJ, Jang SB, Lee JE, Kim KH, Park K. Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. Br J Clin Pharmacol 2007; 64:185-191.
6. Evans WE, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999; 286:487-491.
7. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 2002; 30: 1108-1114.
8. Hustert E, Hbaerl M, Burk O, Wolbold R, He YQ, Klein K, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11:773-779.
9. Hesselink DA, van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Zeier M, et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics 2008; 18:339-348.
10. Barry A, Levine M. A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients. Ther Drug Monit 2010; 32:708-714.
11. Macphee IA, Fredericks S, Mohamed M, Moreton M, Carter ND, Johnston A, et al. Tacrolimus pharmacogenetics: The CYP3A5.*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation 2005; 79:499-502.
12. Zhang X, Liu ZH, Zheng JM, Chen ZH, Tang Z, Chen JS, et al. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin Transplant 2005; 19:638-643.
13. Turolo S, Tirelli AS, Ferraresso M, Ghio L, Belingheri M, Groppali E, et al. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. Pharmacol Rep 2010; 62:1159-1169.
14. Huang W, Lin YS, McConn DJ 2nd, Calamia JC, Totah RA, Isoherranen N, et al. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 2004; 32:1434-1445.
15. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27:383-391.
16. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2009. Available at: http://www.ohri.ca/programs/ clinical-epidemiology/nosgen.pdf. [Accessed 30 March 2012].
17. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-926.
18. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith GD, Altman DG, editors. Systematic reviews in health care. 2nd ed. London: BMJ Publishing Group; 2001.
19. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 2009; 339:b2700.
20. The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. Available at: Www. cochrane-handbook.org [Accessed 28 March 2012].
21. Fukudo M, Yano I, Yoshimura A, Masuda S, Uesugi M, Hosohata K, et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics 2008; 18:413-423.
22. Provenzani A, Notarbartolo M, Labbozzetta M, Poma P, Biondi F, Sanguedolce R, et al. The effect of CYP3A5 and ABCBl single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients. Ann Transplant 2009; 14:23-31.
23. Wei-lin W, Jing J, Shu-sen Z, Li-hua W, Ting-bo L, Song-feng Y, et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl 2006; 12:775-780.
24. Yee M-L, Tan H-H, Sia WJ, Lim GK, Lim KH, Zhao Y. Impact of donor and recipient gene polymorphisms on tacrolimus dosing in Asian liver transplant patients. J Gastroenterol Hepatol 2011; 26:163.
25. Yu S, Wu L, Jin J, Yan S, Jiang G, Xie H, et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation 2006; 81:46-51.
26. Yu S-F, Wu L, Jin J, Yan S, Xie H, Gao J, et al. Influence of genetic polymorphism of donor CYP3A5 on FK506 individual dosage regimen in liver transplantation recipients. Chin Pharm J 2007; 42:314-317.
27. De Wildt SN, Van Schaik RH, Soldin OP, Soldin SJ, Brojeni PY, Van Der Heiden IP, et al. The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation. Eur J Clin Pharmacol 2011; 67:1231-1241.
28. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5:13.
29. Tang HL, Xie HG, Yao Y, Hu YF. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers. Pharmacogenet Genomics 2011; 21:713-720.
30. Terrazzino S, Quaglia M, Stratta P, Canonico PL, Genazzani AA. The effect of CYP3A5 6986A >G and ABCB1 3435C >T on tacrolimus doseadjusted trough levels and acute rejection rates in renal transplant patients: A systematic review and meta-analysis. Pharmacogenet Genomics 2012; 22:642-645.
31. Muraki Y, Usui M, Isaji S, Mizuno S, Nakatani K, Yamada T, et al. Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients. Ann Transplant 2011; 16: 55-62.
32. Barrera-Pulido L, Aguilera-Garcia I, Docobo-Perez F, Alamo-Martinez JM, Pareja-Ciuro F, Nunez-Roldan A, et al. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients. Transplant Proc 2008; 40:2949-2951.
33. Uesugi M, Masuda S, Katsura T, Oike F, Takada Y, Inui K. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics 2006; 16:119-127.
34. Thervet E. Response to pharmacogenetic vs. concentration-controlled optimization of tacrolimus dosing in renal allograft recipients. Clin Pharmacol Ther 2010; 88:597.
35. Gervasini G, Garcia M, Macias RM, Cubero JJ, Caravaca F, Benitez J. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. Transpl Int 2012; 25:471-480.
36. Kim IW, Moon YJ, Ji E, Kim KI, Han N, Kim SJ, et al. Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients. Eur J Clin Pharmacol 2012; 68: 657-669.
37. Cho JH, Yoon YD, Park JY, Song EJ, Choi JY, Yoon SH, et al. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients. Transplant Proc 2012; 44:109-114.
38. Hesselink DA, Bouamar R, Van Gelder T. The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity. Ther Drug Monit 2010; 32: 387-393.
39. Bouamar R, Shuker N, Hesselink DA, Weimar W, Ekberg H, Kaplan B, et al. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: A pooled analysis from three randomizedcontrolled clinical trials. Am J Transplant 2013; 8:1253-1261.